Impact of Azygos Venous Pathway Status on Surgical Difficulty in Patients with Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus: A Retrospective Study with a Large Cohort from China - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Impact of Azygos Venous Pathway Status on Surgical Difficulty in Patients with Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus: A Retrospective Study with a Large Cohort from China

  • By

  • Chaoyan He

  • Rongjin Zhang

  • Hua Zhang

  • Shudong Zhang

  • Shumin Wang

  • February 3, 2026

Share

Objective:

To quantify the azygos-hemiazygos pathway in patients with renal cell carcinoma (RCC) and inferior vena cava (IVC) tumor thrombus by measuring maximum venous width and explore its significance in preoperative surgical planning.

Approach:
    Key Findings:
    • The azygos-hemiazygos pathway serves as a compensatory venous drainage route in patients with RCC and VTT, potentially influencing surgical outcomes.
    • Quantifying the maximum venous width at the aortic hiatus level can help predict surgical difficulty and intraoperative blood loss, aiding in preoperative planning.
    • Temporary clamping of the azygos-hemiazygos pathway may represent a viable strategy to reduce intraoperative bleeding.
    Interpretation:

    The status of the azygos-hemiazygos pathway is a critical factor in surgical planning for patients with RCC and VTT, as it may significantly influence intraoperative outcomes and strategies.

    Limitations:
    • The study is retrospective and may be subject to selection bias, which could affect the generalizability of the findings.
    • The definition of massive hemorrhage is not standardized and may vary across different surgical contexts, complicating comparisons.
    Conclusion:

    Assessing the azygos-hemiazygos pathway can provide valuable insights for surgical strategies in managing RCC with VTT, potentially improving patient outcomes by informing surgical approaches.

Original Source(s)

Impact of Azygos Venous Pathway Status on Surgical Difficulty in Patients with Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus: A Retrospective Study with a Large Cohort from China

  • by Chaoyan He, Rongjin Zhang, Hua Zhang, Shudong Zhang, Shumin Wang

  • February 3, 2026

Related Content

Dana-Farber Research News 12.15.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 16 - 30.

  • December 15, 2025

  • 19 min
Dana-Farber Research News 07.01.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from June 1 - 15.

  • by

  • July 1, 2026

  • 36 min
Dana-Farber Research Supports FDA Approval of Pembrolizumab-Belzutifan Combination for Higher-Risk Clear Cell Kidney Cancer After Surgery

The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2alpha inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, with or without resection of metastatic lesions.

  • by

  • June 12, 2026

  • 3 min